



What is claimed

1. A method of treating a subject suffering from pain comprising periodically administering to the subject a therapeutically effective dose of a compound having the  
5 following structure:



or



wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are independently the same or  
20 different and are hydrogen, a linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3, so as to thereby treat the subject's pain.

25

2. The method of claim 1, wherein one or more of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> or R<sub>4</sub> is a linear chain C<sub>1</sub>-C<sub>6</sub> alkyl group.

3. The method of claim 1, wherein one or more of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> or R<sub>4</sub> is a branched chain C<sub>1</sub>-C<sub>6</sub> alkyl group.

4. The method of claim 1, wherein one or more of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> or R<sub>4</sub> is a benzyl, alkylbenzyl, hydroxybenzyl, alkoxycarbonylbenzyl, aryloxycarbonylbenzyl, carboxybenzyl, nitrobenzyl, cyanobenzyl, or halobenzyl group.

10  
5. The method of claim 1, wherein one or more of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> or R<sub>4</sub> is a phenyl, naphthyl, anthracenyl, pyridinyl, indolyl, furanyl, alkylphenyl, hydroxyphenyl, alkoxycarbonylphenyl, aryloxycarbonylphenyl, nitrophenyl, cyanophenyl, halophenyl group, mercaptophenyl, or aminophenyl group.

15  
6. The method of claim 1, wherein the pain is acute pain.

20  
7. The method of claim 1, wherein the pain is chronic pain.

8. The method of claim 1, wherein the pain is somatogenic pain.

25  
9. The method of claim 8, wherein the somatogenic pain is neuropathic pain.

10. The method of claim 1, wherein the subject is a human being.

11. The method of claim 1, wherein the administration is oral, parenteral, intraperitoneal, intravenous, intramuscular, transdermal, subcutaneous, topical or rectal administration.

5

12. The method of claim 1, wherein the administration is by inhalation, sublingual, nasal, buccal, pulmonary or vaginal administration.

13. The method of claim 1, wherein the periodic administration is effected daily.

14. The method of claim 1, wherein the periodic administration is effected less than or equal to six times a day.

15. The method of claim 14, wherein the periodic administration is effected six times a day.

20

16. The method of claim 1, wherein the therapeutically effective dose is an amount from about 10 mg to about 6,000 mg.

25

17. The method of claim 16, wherein the therapeutically effective dose is an amount from about 500 mg to about 4,000 mg.


18. The method of claim 16, wherein the therapeutically

effective dose is an amount from about 10 mg to about 3,000 mg.


19. The method of claim 18, wherein the therapeutically effective dose is about 3,000 mg.

5

20. The method of claim 18, wherein the therapeutically effective dose is an amount from about 10 mg to about 1,000 mg.
21. The method of claim 20, wherein the therapeutically effective dose is an amount from about 50 mg to about 500 mg.
22. The method of claim 1, wherein the compound has the following structure:



or



25

23. The method of claim 22, wherein the compound is N-(2-n-propylpentanoyl)glycinamide.

24. The method of claim 23, wherein the therapeutically effective dose is 3000 mg/day and the pain is neuropathic pain.

25. The method of claim 22, wherein the compound is N-2(-n-propylpent-2-enoyl)glycinamide.

26. The method of claim 22, wherein one or more of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> or R<sub>4</sub> is a linear chain C<sub>1</sub>-C<sub>6</sub> alkyl group.

27. The method of claim 22, wherein one or more of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> or R<sub>4</sub> is a branched chain C<sub>1</sub>-C<sub>6</sub> alkyl group.

28. The method of claim 22, wherein one or more of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> or R<sub>4</sub> is aralkyl group is a benzyl, alkylbenzyl, hydroxybenzyl, alkoxy carbonylbenzyl, aryloxycarbonylbenzyl, carboxybenzyl, nitrobenzyl, cyanobenzyl, or halobenzyl group.

29. The method of claim 22, wherein one or more of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> or R<sub>4</sub> is a phenyl, naphthyl, anthracenyl, pyridinyl, indolyl, furanyl, alkylphenyl, hydroxyphenyl, alkoxy carbonylphenyl, aryloxycarbonylphenyl, nitrophenyl, cyanophenyl, halophenyl group, mercaptophenyl, or aminophenyl group.

30. The method of claim 22, wherein the pain is acute pain.

31. The method of claim 22, wherein the pain is chronic pain.

32. The method of claim 22, wherein the pain is somatogenic  
5 pain.

33. The method of claim 32, wherein the somatogenic pain is  
neuropathic pain.

34. The method of claim 22, wherein the subject is a human  
being.

35. The method of claim 22, wherein the administration oral,  
parenteral, intraperitoneal, intravenous, intramuscular,  
transdermal, subcutaneous, topical or rectal  
administration.

36. The method of claim 22, wherein the administration is by  
inhalation, sublingual, nasal, buccal, pulmonary or  
vaginal administration.

37. The method of claim 22, wherein the periodic  
administration is effected daily.

25 38. The method of claim 22, wherein the periodic  
administration is effected less than or equal to six  
times a day.

39. The method of claim 38, wherein the periodic administration is effected six times a day.

40. The method of claim 22, wherein the therapeutically effective dose is an amount from about 10 mg to about  
5 6,000 mg.

41. The method of claim 40, wherein the therapeutically effective dose is an amount from about 500 mg to about 4,000 mg.

10 42. The method of claim 40, wherein the therapeutically effective dose is an amount from about 10 mg to about 3,000 mg.

15 43. The method of claim 42, wherein the therapeutically effective dose is about 3,000 mg.


20 44. The method of claim 42, wherein the therapeutically effective dose is an amount from about 10 mg to about 1,000 mg.

45. The method of claim 44, wherein the therapeutically effective dose is an amount from about 50 mg to about 500 mg.


25 46. A method of treating a subject suffering from neuropathic pain comprising administering to the subject 500 mg of N-(2-n-propylpentanoyl)glycinamide six times per day so as to thereby treat the subject's neuropathic pain.

47. A method of preventing pain in a subject predisposed to suffering from pain comprising periodically administering to the subject a prophylactically effective dose of a compound having the following structure:

5



or



15  
1.  $\text{R}_1, \text{R}_2, \text{R}_3$ , and  $\text{R}_4$  are independently the same or different and are hydrogen, a linear or branched  $\text{C}_1\text{-}\text{C}_6$  alkyl group, an aralkyl group, or an aryl group, and  $n$  is an integer which is greater than or equal to 0 and less than or equal to 3, so as to thereby prevent pain in the subject.

20

25

wherein  $\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$  and  $\text{R}_4$  are independently the same or different and are hydrogen, a linear or branched  $\text{C}_1\text{-}\text{C}_6$  alkyl group, an aralkyl group, or an aryl group, and  $n$  is an integer which is greater than or equal to 0 and less than or equal to 3, so as to thereby prevent pain in the subject.

48. The method of claim 47, wherein one or more of  $\text{R}_1$ ,  $\text{R}_2$ ,  $\text{R}_3$  or  $\text{R}_4$  is a linear chain  $\text{C}_1\text{-}\text{C}_6$  alkyl group.

49. The method of claim 47, wherein one or more of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> or R<sub>4</sub> is a branched chain C<sub>1</sub>-C<sub>6</sub> alkyl group.

50. The method of claim 47, wherein one or more of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>

or R<sub>4</sub> is a benzyl, alkylbenzyl, hydroxybenzyl,  
alkoxycarbonylbenzyl, aryloxycarbonylbenzyl,

carboxybenzyl, nitrobenzyl, cyanobenzyl, or halobenzyl  
group.

51. The method of claim 47, wherein one or more of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>

or R<sub>4</sub> is a phenyl, naphthyl, anthracenyl, pyridinyl,  
indolyl, furanyl, alkylphenyl, hydroxyphenyl,  
alkoxycarbonylphenyl, aryloxycarbonylphenyl, nitrophenyl,  
cyanophenyl, halophenyl group, mercaptophenyl, or  
aminophenyl group.

52. The method of claim 47, wherein the pain is acute pain.

53. The method of claim 47, wherein the pain is chronic pain.

20 54. The method of claim 47, wherein the pain is somatogenic  
pain.

55. The method of claim 54, wherein the somatogenic pain is  
neuropathic pain.

25

56. The method of claim 47, wherein the subject is a human  
being.

57. The method of claim 47, wherein the administration is oral, parenteral, intraperitoneal, intravenous, intramuscular, transdermal, subcutaneous, topical or rectal administration.

5 58. The method of claim 47, wherein the administration is by inhalation, sublingual, nasal, buccal, pulmonary or vaginal administration.

10 59. The method of claim 47, wherein the periodic administration is effected daily.

15 60. The method of claim 47, wherein the periodic administration is effected less than or equal to six times a day.


61. The method of claim 60, wherein the periodic administration is effected six times a day.

20 62. The method of claim 47, wherein the prophylactically effective dose is an amount from about 10 mg to about 6,000 mg.


25 63. The method of claim 62, wherein the prophylactically effective dose is an amount from about 500 mg to about 4,000 mg.

64. The method of claim 62, wherein the prophylactically effective dose is an amount from about 10 mg to about 3,000 mg.

65. The method of claim 64, wherein the prophylactically effective dose is about 3,000 mg.
66. The method of claim 64, wherein the prophylactically effective dose is an amount from about 10 mg to about 1,000 mg.
67. The method of claim 66, wherein the prophylactically effective dose is an amount from about 50 mg to about 500 mg.
68. The method of claim 47, wherein the compound has the following structure:



or



69. The method of claim 68, wherein the compound is N-(2-n-propylpentanoyl)glycinamide.

70. The method of claim 69, wherein the prophylactically effective dose is 3000 mg/day and the pain is neuropathic  
5 pain.

71. The method of claim 68, wherein the compound is N-2(-n-propylpent-2-enoyl)glycinamide.

10 72. The method of claim 68, wherein one or more of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> or R<sub>4</sub> is a linear chain C<sub>1</sub>-C<sub>6</sub> alkyl group.

73. The method of claim 68, wherein one or more of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> or R<sub>4</sub> is a branched chain C<sub>1</sub>-C<sub>6</sub> alkyl group.

20 74. The method of claim 68, wherein one or more of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> or R<sub>4</sub> is aralkyl group is a benzyl, alkylbenzyl, hydroxybenzyl, alkoxy carbonylbenzyl, aryloxycarbonylbenzyl, carboxybenzyl, nitrobenzyl, cyanobenzyl, or halobenzyl group.

25 75. The method of claim 68, wherein one or more of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> or R<sub>4</sub> is a phenyl, naphthyl, anthracenyl, pyridinyl, indolyl, furanyl, alkylphenyl, hydroxyphenyl, alkoxy carbonylphenyl, aryloxycarbonylphenyl, nitrophenyl, cyanophenyl, halophenyl group, mercaptophenyl, or aminophenyl group.

76. The method of claim 68, wherein the pain is acute pain.

77. The method of claim 68, wherein the pain is chronic pain.

78. The method of claim 68, wherein the pain is somatogenic pain.

5

79. The method of claim 78, wherein the somatogenic pain is neuropathic pain.

80. The method of claim 68, wherein the subject is a human being.

10

81. The method of claim 68, wherein the administration oral, parenteral, intraperitoneal, intravenous, intramuscular, transdermal, subcutaneous, topical or rectal administration.

15

82. The method of claim 68, wherein the administration is by inhalation, sublingual, nasal, buccal, pulmonary or vaginal administration.

20

83. The method of claim 68, wherein the periodic administration is effected daily.

25

84. The method of claim 68, wherein the periodic administration is effected less than or equal to six times a day.

85. The method of claim 68, wherein the periodic

administration is effected six times a day.

86. The method of claim 68, wherein the prophylactically effective dose is an amount from about 10 mg to about 6,000 mg.

5

87. The method of claim 86, wherein the prophylactically effective dose is an amount from about 500 mg to about 4,000 mg.

10  
15  
20  
25

88. The method of claim 86, wherein the prophylactically effective dose is an amount from about 10 mg to about 3,000 mg.

89. The method of claim 88, wherein the prophylactically effective dose is about 3,000 mg.

90. The method of claim 88, wherein the prophylactically effective dose is an amount from about 10 mg to about 1,000 mg.

20

91. The method of claim 90, wherein the prophylactically effective dose is an amount from about 50 mg to about 500 mg.


25

92. A method of preventing neuropathic pain in a subject predisposed to suffering from neuropathic pain comprising administering to the subject 500 mg of N-(2-n-propylpentanoyl)glycinamide six times per day so as to thereby prevent the neuropathic pain in the subject.


93. A method of treating a subject suffering from pain comprising periodically administering to the subject a pharmaceutical composition comprising a therapeutically effective dose a compound having the following structure:

5

150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995  
1000



or



20

wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are independently the same or different and are hydrogen, a linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3,


25

and a pharmaceutically acceptable carrier, so as to thereby treat the subject's pain.


94. A method of preventing pain in a subject predisposed to

suffering from pain comprising periodically administering to the subject a composition comprising a prophylactically effective dose of a compound having the following structure:

5



or



PRINTED IN U.S.A. ON DECEMBER 10, 1973. THE ORIGINAL IS IN THE LIBRARY OF THE UNITED STATES PATENT AND TRADEMARK OFFICE.


20

wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are independently the same or different and are hydrogen, a linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3,

and a pharmaceutically acceptable carrier, so as to thereby prevent pain in the subject.


25

95. A method of treating a subject suffering from a headache disorder comprising periodically administering to the subject a therapeutically effective dose of a compound having the following structure:



5


or



15  
wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are independently the same or different and are hydrogen, a linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3, so as to thereby treat the headache disorder.


20

96. A method of preventing a headache disorder in a subject predisposed to suffering from a headache disorder comprising periodically administering to the subject a prophylactically effective dose of a compound having the following structure:



5

or



15

wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are independently the same or different and are hydrogen, a linear or branched C<sub>1</sub>-C<sub>6</sub> alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3, so as to thereby prevent the headache disorder in the subject.